TomoTherapy Inc. today announced that it has received clearance from the U.S. Food and Drug Administration for its TomoDirect radiation therapy technology, a new discrete-angle, sliding-beam delivery mode for the Hi·Art treatment system.
Developed as a complement to helical TomoTherapy, TomoDirect’s two modes utilize the same binary multi-leaf collimator and CT-style gantry technology. Tumor volume and surrounding organs at risk will dictate which modality to use for a given case. Clinicians will be able to choose from several discrete angles as well as the optimal modulation level required for delivery.
According to TomoTherapy, the technology is expected to provide significant time savings in the planning and delivery phases for several clinical scenarios, including whole breast irradiation and palliative treatments.
